@col69 to briefly summarise an earlier and lengthy post of mine,...

@col69 to briefly summarise an earlier and lengthy post of mine, I personally think DEP-Docetaxel is/will be a dud and not guaranteed to get partnered.

The limited patent life (primarily until 2032 with potential extension up to 5 years but not guaranteed) is going to be an issue IMO.

My estimated timelines (if partnered):
2023: Partner signed to take DEP-Docetaxel into a Phase 3 trial.
2023/2024: Phase 3 trial commences
2026/2027: Phase 3 trial complete
2027: Full results read out.
2028: If trial successful, one full year for NDA submission and possible FDA approval.
2029: Potential first sales of DEP-Docetaxel.

However, given the primary and guaranteed patent coverage runs out in 2032 I have serious doubts that Starpharma will be able to sign a partner with a meaningful deal in the first place to actually take the drug into Phase 3. Not with such little guaranteed patent protection of only 3 years.

DYOR

P.S. Better patent life on the other two internal DEP candidates